Corticotrophs are adrenocorticotropic hormone (ACTH)-producing cells in the anterior pituitary. They regulate the hypothalamic-pituitary-adrenal (HPA) axis and stress responses.
Lactotrophs is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
- Cell Type: Acidophilic endocrine cells
- Size: 12-18 μm diameter
- Granulation: Moderate secretory granules containing prolactin
- Distribution: Primarily in the posterior-lateral region of anterior pituitary
- Marker Proteins: Prolactin (PRL), Pit-1 transcription factor
| Marker |
Function |
| Prolactin (PRL) |
Primary secreted hormone |
| Pit-1 |
Transcription factor for PRL and GH |
| D2R |
Dopamine D2 receptor (primary inhibitor) |
| ERα |
Estrogen receptor α |
| TRH |
Thyrotropin-releasing hormone (stimulator) |
- Reproductive Function:
- Mammary gland development and milk synthesis
- Modulation of reproductive behaviors
- Immune Regulation: Immunomodulatory effects
- Brain Function:
- Myelin maintenance
- Neuroprotection
- Stress response modulation
- Metabolic Effects: Lipid metabolism, insulin sensitivity
- Primary Inhibitor: Dopamine (tonically suppresses secretion)
- Stimulators: Estrogen, TRH, oxytocin, stress
- Feedback: Prolactin itself provides negative feedback
- Prolactin Alterations: Elevated PRL in AD (possible compensatory neuroprotection)
- Estrogen Connection: PRL- estrogen interactions affect AD progression
- Neuroprotective Effects: PRL has shown neuroprotective properties
- Research: PRL analogs explored for cognitive enhancement
- PRL Modulation: Abnormal PRL secretion patterns
- Dopamine Connection: Lactotrophs are dopamine-sensitive (relevant to PD)
- Therapeutic Target: Dopamine agonists affect PRL secretion
- Immunomodulation: PRL can influence autoimmune responses
- Disease Activity: PRL levels correlate with MS disease activity
Lactotrophs express:
- PRL (Prolactin gene)
- PIT1 (Pituitary-specific transcription factor)
- DRD2 (Dopamine D2 receptor)
- ESR1 (Estrogen receptor α)
- TRHR (TRH receptor)
- OXTR (Oxytocin receptor)
- Dopamine Agonists: Bromocriptine, cabergoline (reduce PRL)
- PRL Antagonists: Experimental approaches
- PRL Mimetics: For neuroprotective effects
- Hyperprolactinemia: Causes galactorrhea, hypogonadism
- Treatment goals: Normalize PRL, restore fertility
- Drug interactions: Antipsychotics can elevate PRL
- Neuroprotection Mechanisms: PRL-mediated neuroprotection pathways
- Biomarkers: PRL as biomarker for neurodegeneration
- Therapeutic Applications: PRL-targeted therapies for AD/PD
These pituitary cell types are essential for endocrine regulation. Dysfunction can lead to various hormonal disorders including hyperprolactinemia, Cushing's disease, and thyroid disorders. In neurodegenerative diseases, endocrine changes may influence disease progression.
Research employs immunohistochemistry to identify cell types, electron microscopy to study granule morphology, and hormone assays to measure secretion patterns. Cell culture models help study pituitary cell function.
Understanding these cell types is important for developing endocrine therapies. Dopamine agonists (e.g., bromocriptine, cabergoline) treat prolactinomas by inhibiting lactotrophs. Surgical and radiotherapeutic approaches target functioning pituitary adenomas.
The study of Lactotrophs has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Shulman LM, et al. Prolactin in neurological disorders. J Neurol Sci. 2018.
- Costanza M, et al. Prolactin and neuroprotection. Prog Brain Res. 2020.
- Freeman ME, et al. Prolactin: an overview. Endocr Rev. 2019.
- Ben-Jonathan N, et al. Extrapituitary prolactin. Front Horm Res. 2017.
5.calar G, et al. Prolactin and immune function. J Neuroimmunol. 2021.
- DeRosa M, et al. Prolactin in neurodegeneration. Curr Drug Targets. 2018.
- Marrades MP, et al. Prolactin alterations in Alzheimer's disease. J Alzheimers Dis. 2019.
- González H, et al. Prolactin receptor in the brain. Neuroendocrinology. 2022.